SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure following disappointing quarterly delivery figures and intensifying competition in the EV sector. Investors are actively debating the company's long-term prospects as capital increasingly shifts toward anticipation of the upcoming SpaceX IPO.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying following a strong quarterly earnings report that beat analyst expectations and provided a positive outlook for the year. The community is actively debating the stock's potential for a long-term turnaround fueled by the growing demand for energy storage and AI infrastructure, while some traders remain cautious about broader solar sector headwinds.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following the announcement of subscription price increases across all U.S. tiers, a move that analysts view as a strategic leverage of pricing power to fuel content investment. While the community is split between bullish sentiment over potential revenue gains and frustration regarding rising costs, traders are closely watching the stock for a breakout above the key 100 level as volume and institutional interest pick up.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing significant trading activity driven by persistent market speculation regarding a potential acquisition by major tech and space players like Amazon or SpaceX. The community is actively debating the strategic value of the company's spectrum assets and the impact of Apple's existing partnership, with many long-term shareholders dismissing lower buyout rumors as undervaluation.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently experiencing intense volatility and downward pressure following a recent reverse split, leaving the community deeply divided between frustrated long-term shareholders and short-sellers profiting from the decline. Investors are actively debating the company's long-term viability, citing concerns over management's silence on financial guidance and a lack of major sports network partnerships, while some traders continue to look for potential short-squeeze opportunities.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Investors in Luckin Coffee are closely watching for potential catalysts like a possible relisting and the strategic implications of the Blue Bottle Coffee acquisition, while debating the impact of ongoing market volatility on the company's valuation. Community discussion is dominated by long-term holders expressing frustration over price suppression, even as others continue to accumulate shares based on strong growth fundamentals and a belief in a coming rebound.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing a surge in investor attention as market sentiment shifts toward its critical role in AI infrastructure, with community focus centering on massive potential orders from major hyperscalers like Google and the company's pivot to high-volume semiconductor testing. Traders are closely watching for validation of these large-scale deployments, treating the stock as a high-conviction play on the structural expansion of AI-driven chip demand.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following the FDA approval of VYKAT XR, the first treatment for hyperphagia in patients with Prader-Willi syndrome. Investors are actively discussing the stock's significant valuation shift from a clinical-stage biotech to a commercial-stage company, while monitoring the potential for a long-term buyout in a sector seeing heavy consolidation.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is currently trending as investors focus on the upcoming April 9th earnings report, with community sentiment split between high expectations for revenue growth from QNX-led automotive contracts and skepticism regarding historical guidance performance. Bulls are pointing to the integration of QNX in next-generation vehicle architectures as a major catalyst for long-term value, while shorts and skeptics continue to monitor the companys ability to move beyond stagnant revenue figures and prove sustained profitability.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix (ENVX) is currently experiencing high volatility as investors weigh the company's long-term potential in high-energy density batteries against ongoing manufacturing bottlenecks at its Malaysia facility. While community sentiment remains polarized, many participants are focused on the impact of a recent share repurchase program, the search for a major commercial purchase order, and whether the firm can successfully navigate production scaling to validate its silicon-anode technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026.</li><li>The company’s total revenue for fiscal 2025 is projected around $370.2 million to $370.4 million.</li><li>Looking ahead, the company has set a revenue forecast for fiscal 2026 between $365 million and $375 million.</li></ul>InMode (INMD) stock is gaining investor attention in Friday’s premarket after the medical technology provider announced its fourth quarter (Q4) sales outlook.The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data.&nbsp;<h2 class="st-heading-2">2025 And 2026 Outlook&nbsp;</h2>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026. The company’s total revenue for fiscal 2025 is projected to be around $370.2 million to $370.4 million, below the analysts' consensus estimate of $371 million, as per FiscalAI data.InMode expects a non-GAAP gross margin near the high end of the 70% range for the full 2025 fiscal year.&nbsp;Looking ahead, the company has set a revenue forecast for fiscal 2026 between approximately $365 million and $375 million.&nbsp;<a href="https://stocktwits.com/symbol/INMD">InMode stock</a> inched 0.8% higher in Friday’s premarket.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory while message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_09_055125_png_79a97af5f3.webp" alt="INMD’s Sentiment Meter and Message Volume as of 05:45 a.m. ET on Jan. 9, 2026 | Source: Stocktwits" width="926" height="105"></figure>A bullish Stocktwits user highlighted sequential growth and high margins.&nbsp;<stembedurl>https://stocktwits.com/thinkandpick/message/641307067</stembedurl>Another user pointed to ongoing pressure in the aesthetic device sector, noting that demand remains subdued, but added that the latest outlook broadly aligns with the company’s earlier outlook for 2025, suggesting performance is tracking as expected.<stembedurl>https://stocktwits.com/findingthestock/message/641285697</stembedurl><h2 class="st-heading-2">Brokerage Radar&nbsp;</h2>In December, Canaccord cut its price target on InMode to $15 from $16 and kept a ‘Hold’ rating on the stock, according to TheFly. The firm said it still has a positive long-term view on the medical technology industry going into 2026, noting that mid-sized company valuations remain low, and deal activity is increasing.INMD stock has declined by over 10% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-big-oil-invest-at-least-100-billion-venezuela/cmU29w3R4d2">Trump Says Big Oil Will Invest At Least $100 Billion To Rebuild Venezuela's Oil Infrastructure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 A worker produces medical instrument at Shandong Yixing Medical Instrument Co., Ltd.

INMD Stock Draws Investor Attention On Q4 Financial Update

The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data. 

Equity

The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data. 


UBS says this sector remains a high-quality, defensive investment theme

Investing.com -- UBS continues to view the medical devices sector as a high-quality, defensive investment theme, supported by long-term demographic shifts and rising global demand.

Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick

Investing.com -- Citi analysts revised their MedTech coverage following a volatile first quarter, with several rating changes and adjustments to target prices.

HSBC shuffles MedTech stocks, cutting 4, upgrading 2

Investing.com -- HSBC has reshuffled its ratings across the MedTech and Life Sciences sector, upgrading   Siemens  Healthineers AG  (ETR:SHLG) and Sonova (SIX:SOON) to Buy while cutting  Align Technology  (NASDAQ:ALGN), Eurofins Scientific SE (EPA:EUFI), IQVIA, and Smith&Nephew (LON:SN) to Hold.

Are Wall Street Analysts Predicting Cooper Companies Stock Will Climb or Sink?

Cooper Companies has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

DexCom, a manufacturer of glucose monitoring systems for diabetes management, witnessed a 19% rise in the number of watchers on Stocktwits over the last week. The renewed interest in the stock came after the firm surprisingly trimmed its full-year sales forecast, a move that immediately pushed its shares down by 40%.The firm now anticipates full-year revenue of $4.00-$4.05 billion versus an earlier guidance of $4.20-$4.35 billion. Analysts did not take the significant revision lightly and raised concerns during the earnings call. DexCom management cited factors like sales force disruption and a decline in market share as some of the primary reasons that led to the guidance trim.Meanwhile, the company reported a 15% rise in its second quarter revenue at $1 billion while net income rose 24%YoY to $143.50 million. Volume growth in conjunction with strong new customer additions continued to be the primary driver of revenue growth.The firm’s sensor segment witnessed a 22% YoY rise in revenue at $947 million while hardware revenue declined 39% to $57.30 million.Kevin Sayer, Dexcom’s chairman, president and CEO stated that the firm’s execution did not meet its high standards. The firm cited a decline in new customers, lower revenue per patient and higher-than-expected rebates as reasons for its sales guidance cut.Meanwhile, JPMorgan downgraded the stock to ‘Neutral’ from ‘Overweight’ while reducing the price target to $75 from $145. The firm’s analyst said the second-quarter update was a sharp turn in the wrong direction for the firm.However, retail sentiment is currently trending in the bullish territory (56/100) as investors’ confidence was buoyed by the firm’s $750 million share repurchase program.<figure class="image"><a href="https://stocktwits.com/symbol/DXCM"><img style="aspect-ratio:790/219;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_31_at_12_31_30_PM_317bed394d.png" alt="Stocktwits sentiment trends in bullish zone for DexCom" width="790" height="219"></a><figcaption>Stocktwits sentiment trends in bullish zone for DexCom</figcaption></figure>DexCom hasn’t recovered from the 40% decline but retail investors anticipate the share repurchase may help in recouping some of the losses. One Stocktwits user named ‘MoonWalk3000’ expressed optimism about the company’s buyback decision and said this is a good way to improve the book value of the stock.<figure class="image"><a href="https://stocktwits.com/MoonWalk3000/message/580825054"><img style="aspect-ratio:788/695;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_31_at_12_32_42_PM_927efc54e2.png" alt="Stocktwits user MoonWalk3000's post on DexCom" width="788" height="695"></a><figcaption>Stocktwits user MoonWalk3000's post on DexCom</figcaption></figure>

DexCom Crashed 40% In A Single Day Last Week; Gains 19% More Stocktwits Watchers

The firm revised down its full-year sales guidance which led to a slew of analyst downgrades. Retail investors are betting on the $750 million share repurchase program announced by the firm to buoy shares.

Current Price	$78.13
Prev Close	$78.21
Open	$78.21
Dividend Yield	N/A
50-Day Moving Average	$83.80
Beta	N/A
Avg. Volume	21,861.87
PE Ratio	N/A

52-Week High	$93.62
52-Week Low	$71.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

XHE
SPDR S&P Health Care Equipment ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XHE News

XHESPDR S&P Health Care Equipment ETF